Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS9 | O00182 | 5/20 | 0.60 |
| ▸ | LGALS1 | P09382 | 5/20 | 0.60 |
| ▸ | LGALS7; LGALS7B | P47929 | 4/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 7/20 | 0.46 |
| ▸ | SELE | P16581 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773524 | 0.90 | LGALS3 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL12886326 | 0.88 | LGALS3 (0.62) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL17880710 | 0.86 | LGALS3 (0.52) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL15075146 | 0.84 | LGALS3 (0.62) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL16642280 | 0.84 | LGALS3 (0.49) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 | |
| SCHEMBL6570199 | 0.84 | LGALS9 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB | |
| SCHEMBL7141014 | 0.84 | LGALS9 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB | |
| SCHEMBL6570202 | 0.84 | LGALS9 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB | |
| SCHEMBL7144990 | 0.84 | LGALS9 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB | |
| SCHEMBL4954660 | 0.84 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160144016-A1 | SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE | SYNGLYCO PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160144016-A1 | SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE | DDOST, FUT5, FUT6 | LGALS3 42/4885LGALS9 134/4885LGALS1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.